[
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech",
    "summary": "Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company’s legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the...",
    "url": "https://finnhub.io/api/news?id=a402e4c9f5e745d2ce8682066332eeec2aa700fbc8482fe307419d2345d4ea62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750354400,
      "headline": "Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech",
      "id": 135414051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company’s legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the...",
      "url": "https://finnhub.io/api/news?id=a402e4c9f5e745d2ce8682066332eeec2aa700fbc8482fe307419d2345d4ea62"
    }
  },
  {
    "ts": null,
    "headline": "What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?",
    "summary": "LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.",
    "url": "https://finnhub.io/api/news?id=671bceb1503c75560f2191e89a2d40373d0d521150c0da86026f66bb88304848",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750342980,
      "headline": "What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?",
      "id": 135396761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.",
      "url": "https://finnhub.io/api/news?id=671bceb1503c75560f2191e89a2d40373d0d521150c0da86026f66bb88304848"
    }
  },
  {
    "ts": null,
    "headline": "SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls",
    "summary": "The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Cantor Fitzgerald upgraded Analog Devices (ADI) to Overweight from Neutral with a price target of $270, up from $250. Analog Devices is a “best-in-class” analog company, with “outsized” industrial exposure which is preferential into the upcycle, the firm tells investors in a research note. Argus upgrad",
    "url": "https://finnhub.io/api/news?id=1492fe234c164999b387864c252e89730a3be937ed33f5f3b8f1b9ab22a41a81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750340738,
      "headline": "SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls",
      "id": 135391336,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Cantor Fitzgerald upgraded Analog Devices (ADI) to Overweight from Neutral with a price target of $270, up from $250. Analog Devices is a “best-in-class” analog company, with “outsized” industrial exposure which is preferential into the upcycle, the firm tells investors in a research note. Argus upgrad",
      "url": "https://finnhub.io/api/news?id=1492fe234c164999b387864c252e89730a3be937ed33f5f3b8f1b9ab22a41a81"
    }
  },
  {
    "ts": null,
    "headline": "RyboDyn Selected to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome",
    "summary": "RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, today announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Eli Lilly and Company's global scientific and business network—a critical catalyst as it advances its lead programs.",
    "url": "https://finnhub.io/api/news?id=24be2c8a3f81f5104d32bf705c0306d1f48fd0d5f71b64340e45e180d419d23b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750334580,
      "headline": "RyboDyn Selected to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome",
      "id": 135395727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, today announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Eli Lilly and Company's global scientific and business network—a critical catalyst as it advances its lead programs.",
      "url": "https://finnhub.io/api/news?id=24be2c8a3f81f5104d32bf705c0306d1f48fd0d5f71b64340e45e180d419d23b"
    }
  },
  {
    "ts": null,
    "headline": "How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl",
    "summary": "In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.",
    "url": "https://finnhub.io/api/news?id=fb958c96dcdd5260d172c1218f5b1f54bc21509a9afc5db51e57c77fd2ef6641",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750334437,
      "headline": "How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl",
      "id": 135388323,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.",
      "url": "https://finnhub.io/api/news?id=fb958c96dcdd5260d172c1218f5b1f54bc21509a9afc5db51e57c77fd2ef6641"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs",
    "summary": "NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.",
    "url": "https://finnhub.io/api/news?id=4998039328044db365d962966ab2be03463d034811ed00c668b46cc78aaa8628",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750334126,
      "headline": "Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs",
      "id": 135396765,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.",
      "url": "https://finnhub.io/api/news?id=4998039328044db365d962966ab2be03463d034811ed00c668b46cc78aaa8628"
    }
  },
  {
    "ts": null,
    "headline": "The Fed's Faced With Macroeconomic Complexity",
    "summary": "The Fed's latest statement tones down concerns about the economy. Explore the Fed's latest stance on growth and inflation, and why rate hikes are unlikely.",
    "url": "https://finnhub.io/api/news?id=2b09bac2f67bebf5ab97da265deeb0fe8dfd5285092ecf5e40987f5efc6aaf21",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750329002,
      "headline": "The Fed's Faced With Macroeconomic Complexity",
      "id": 135394542,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/459229485/image_459229485.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Fed's latest statement tones down concerns about the economy. Explore the Fed's latest stance on growth and inflation, and why rate hikes are unlikely.",
      "url": "https://finnhub.io/api/news?id=2b09bac2f67bebf5ab97da265deeb0fe8dfd5285092ecf5e40987f5efc6aaf21"
    }
  },
  {
    "ts": null,
    "headline": "Rybodyn Selects to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome",
    "summary": "RyboDyn Inc. announced its selection to join Lilly Gateway Labs in San Diego, an innovation hub operated with Alexandria Real Estate Equities Inc. This selection provides RyboDyn with direct access...",
    "url": "https://finnhub.io/api/news?id=d94e317abac7dd023763afe64262338e34ec94bb7c2e6665d25eda9feff7e7ec",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750323021,
      "headline": "Rybodyn Selects to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome",
      "id": 135388410,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "RyboDyn Inc. announced its selection to join Lilly Gateway Labs in San Diego, an innovation hub operated with Alexandria Real Estate Equities Inc. This selection provides RyboDyn with direct access...",
      "url": "https://finnhub.io/api/news?id=d94e317abac7dd023763afe64262338e34ec94bb7c2e6665d25eda9feff7e7ec"
    }
  },
  {
    "ts": null,
    "headline": "5 Growth Stocks to Invest $1,000 in Right Now",
    "summary": "Nvidia and Taiwan Semiconductor Manufacturing are two of the best ways to play the AI infrastructure buildout.  Eli Lilly has benefited from the GLP-1 weight-loss drug craze, and its newest drug candidate may be its next big growth driver.  While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle East, now can still be a good time to invest in growth stocks.",
    "url": "https://finnhub.io/api/news?id=1d5e83ded7411ab2fb0e8e8c4631bcbbb70f847ad06d575501c4e71940946153",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750319700,
      "headline": "5 Growth Stocks to Invest $1,000 in Right Now",
      "id": 135388070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nvidia and Taiwan Semiconductor Manufacturing are two of the best ways to play the AI infrastructure buildout.  Eli Lilly has benefited from the GLP-1 weight-loss drug craze, and its newest drug candidate may be its next big growth driver.  While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle East, now can still be a good time to invest in growth stocks.",
      "url": "https://finnhub.io/api/news?id=1d5e83ded7411ab2fb0e8e8c4631bcbbb70f847ad06d575501c4e71940946153"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks",
    "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best and worst performers in the branded pharmaceuticals industry.",
    "url": "https://finnhub.io/api/news?id=5b323eeaea899fb8ef7aa749afc0ecb414febe398fecb20c815b3e1f5265edb8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750304374,
      "headline": "Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks",
      "id": 135414052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best and worst performers in the branded pharmaceuticals industry.",
      "url": "https://finnhub.io/api/news?id=5b323eeaea899fb8ef7aa749afc0ecb414febe398fecb20c815b3e1f5265edb8"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting with Eli Lilly (NYSE:LLY).",
    "url": "https://finnhub.io/api/news?id=54dbe093864c3f6c439a9102c33655636b61814b3f0c6087941fa14a96349525",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750303865,
      "headline": "Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks",
      "id": 135398619,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting with Eli Lilly (NYSE:LLY).",
      "url": "https://finnhub.io/api/news?id=54dbe093864c3f6c439a9102c33655636b61814b3f0c6087941fa14a96349525"
    }
  }
]